In this on-demand webcast of a live symposium, expert faculty use case studies to highlight the latest safety and efficacy evidence supporting optimal management of patients with HER2-positive breast cancer.
In this commentary, 2 oncologists, an oncology nurse, and a pharmacist discuss how recent data on HER2-targeted treatment are changing the therapeutic paradigm in early and metastatic breast cancer.
Sara Tolaney, MD, MPH, reviews recent clinical trial data showing survival benefits from newer targeted agents in the setting of HER2-positive, advanced breast cancer with brain metastases.
Download these slides summarizing key points from a live Cancer Conversations webinar on optimizing the management of patients with HER2+ breast cancer using currently available HER2-directed therapies.
Use this Interactive Decision Support Tool to compare your choice of therapy for patients with HER2+ MBC with those of 5 renowned experts.
Listen in as expert faculty discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer, as well as potential implications of new data in clinical practice.
Download these slides summarizing key points from a recent podcast with expert discussion on key insights and the most recent data for the management of patients with HER2-positive breast cancer.